In the last trading session, 1.4 million Perspective Therapeutics Inc (AMEX:CATX) shares changed hands as the company’s beta touched 1.11. With the company’s per share price at $3.32 changed hands at $0.2 or 6.41% during last session, the market valuation stood at $246.44M. CATX’s last price was a discount, traded about -398.49% off its 52-week high of $16.55. The share price had its 52-week low at $1.60, which suggests the last value was 51.81% up since then.
Analysts gave the Perspective Therapeutics Inc (CATX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.14. If we narrow down to specifics, the data shows that 0 out of 4 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CATX as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight.
Perspective Therapeutics Inc (AMEX:CATX) trade information
Instantly CATX was in green as seen at the end of in last trading. With action 29.18%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 4.08%, with the 5-day performance at 29.18% in the green. However, in the 30-day time frame, Perspective Therapeutics Inc (AMEX:CATX) is 41.28% up.
The consensus price target for the stock as assigned by Wall Street analysts is 21, meaning bulls need an upside of 84.19% from its current market value. According to analyst projections, CATX’s forecast low is 3 with 24 as the target high. To hit the forecast high, the stock’s price needs a -622.89% plunge from its current level, while the stock would need to tank 9.64% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -9.86%. The 2025 estimates are for Perspective Therapeutics Inc earnings to increase by 6.46%, but the outlook for the next 5-year period is at -1.94% per year.
CATX Dividends
Perspective Therapeutics Inc is expected to release its next quarterly earnings report in July.
Among Mutual Funds, the top two as of Mar 31, 2025 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund . With 1.69 shares estimated at $5.63 million under it, the former controlled 2.28% of total outstanding shares. On the other hand, Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund held about 2.21% of the shares, roughly 1.64 shares worth around $5.45 million.
